In NSCLC cell migration assays, they demonstrate a statistically significant reduction in migration by RAC1 inhibition, an effect that they believe is due in part to NF-κB via the transactivation of migratory genes [5]. Here, RAC1 is linked to non-small cell lung carcinoma.